Sheng Meng-Yao, Zhou Yuan, Xu Ming-Jiang, Yang Feng-Chun
State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China.
State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China. E-mail:
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Aug;22(4):1183-7. doi: 10.7534/j.issn.1009-2137.2014.04.057.
Additional sex comb-like 1 ( ASXL1) is an enhancer of Trithorax and Polycomb family, which are necessary for the maintenance of stable repression of homeotic and other loci. Recently, alterations of ASXL1 gene were identified in the hematopoietic cells from patients with a variety of myeloid malignancies, including chronic myelomonocytic leukemia (CMML, 43% of cases), myelodysplastic syndrome (MDS, 20%), myeloproliferative neoplasms (MPN, 10%) and acute myeloid leukemia (AML, 20%). The majority of ASXL1 mutations are frameshift and nonsense mutations. These clinical data suggest an important role of ASXL1 in the pathogenesis and/or transformation of myeloid malignancies. However, the role of ASXL1 in the pathogenesis of myeloid malignancies and in normal hematopoiesis in vivo, as well as the underlying mechanisms remains unknown. This article reviews the structure and function of ASXL1, the clinical characteristic and prognostic significance of ASXL1 mutation, the association of ASXL1 with other gene mutation, as well as ASXL1 knock-down or silence in vitro and in vivo models.
附加性梳状蛋白1(ASXL1)是三胸节蛋白和多梳蛋白家族的增强子,它们对于维持同源异型基因座和其他基因座的稳定抑制是必需的。最近,在患有多种髓系恶性肿瘤的患者的造血细胞中发现了ASXL1基因的改变,这些恶性肿瘤包括慢性粒单核细胞白血病(CMML,43%的病例)、骨髓增生异常综合征(MDS,20%)、骨髓增殖性肿瘤(MPN,10%)和急性髓系白血病(AML,20%)。大多数ASXL1突变是移码突变和无义突变。这些临床数据表明ASXL1在髓系恶性肿瘤的发病机制和/或转化中起重要作用。然而,ASXL1在髓系恶性肿瘤发病机制和体内正常造血中的作用以及潜在机制仍不清楚。本文综述了ASXL1的结构和功能、ASXL1突变的临床特征和预后意义、ASXL1与其他基因突变的关联,以及ASXL1在体外和体内模型中的敲低或沉默情况。